Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myelogenous leukemia after tyrosine kinase inhibitor treatment

References

• Chen X, Chen Y, Zhang M, et al. HucMSC exosomes promoted imatinib-induced apoptosis in K562-R cells via a miR-145a-5p/USP6/GLS1 axis. Cell Death Dis. 2022;13(1):92. doi:10.1038/s41419-022-04531-3
   PubMed Web of Science ®Google Scholar
• Habib EM, Nosiar NA, Eid MA, et al. MiR-150 expression in chronic myeloid leukemia: relation to imatinib response. Lab Med. 2022;53(1):58–64. doi:10.1093/labmed/lmab040
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022;97(9):1236–1256.
   PubMed Web of Science ®Google Scholar
• Ciftciler R, Haznedaroglu IC. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. Eur Rev Med Pharmacol Sci. 2021;25(24):7787–7798.
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang J, Deng X, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res: CR. 2020;39(1):204. doi:10.1186/s13046-020-01709-5
   PubMed Web of Science ®Google Scholar
• Antic D, Jovanovic MP, Fekete MD, et al. Assessment of bone marrow microvessel density in chronic lymphocytic leukemia. Appl Immunohistochem Mol Morphol. 2010;18(4):353–356. doi:10.1097/PAI.0b013e3181d18ae2
   PubMedGoogle Scholar
• Kvasnicka HM, Thiele J. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol. 2004;19(4):1245–1260.
   PubMed Web of Science ®Google Scholar
• Cojbasic I, Macukanovic-Golubovic L, Mihailovic D, et al. The significance of angiogenesis for predicting optimal therapeutic response in chronic myeloid leukaemia patients. Pol J Pathol. 2017;68(3):241–251. doi:10.5114/pjp.2017.71532
   PubMed Web of Science ®Google Scholar
• Yeh CH, Moles R, Nicot C. Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer. 2016;15(1):37. doi:10.1186/s12943-016-0518-2
   PubMedGoogle Scholar
• Ufkin ML, Peterson S, Yang X, et al. miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk Res. 2014;38(3):402–410. doi:10.1016/j.leukres.2013.12.021
   PubMed Web of Science ®Google Scholar
• Martins JRB, Moraes LN, Cury SS, et al. MiR-125a-3p and MiR-320b differentially expressed in patients with chronic myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation and imatinib mesylate. Int J Mol Sci. 2021;22(19).
   Web of Science ®Google Scholar
• Shen X, Si Y, Yang Z, et al. MicroRNA-542-3p suppresses cell growth of gastric cancer cells via targeting oncogene astrocyte-elevated gene-1. Med Oncol. 2015;32(1):361. doi:10.1007/s12032-014-0361-5
   PubMed Web of Science ®Google Scholar
• Zhao J, Lu Q, Zhu J, et al. Prognostic value of miR-96 in patients with acute myeloid leukemia. Diagn Pathol. 2014;9:76.
   PubMed Web of Science ®Google Scholar
• Habib EM, Nosiar NA, Eid MA, et al. Circulating miR-146a expression predicts early treatment response to imatinib in adult chronic myeloid leukemia. J Investig Med. 2021;69(2):333–337. doi:10.1136/jim-2020-001563
   PubMed Web of Science ®Google Scholar
• Cao LL, Lu H, Soutto M, et al. Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-gamma signalling. Gut. 2023.
   Web of Science ®Google Scholar
• Litwinska Z, Machalinski B. miRNAs in chronic myeloid leukemia: small molecules, essential function. Leuk Lymphoma. 2017;58(6):1297–1305. doi:10.1080/10428194.2016.1243676
   PubMed Web of Science ®Google Scholar
• Rittavee Y, Artus J, Desterke C, et al. miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells. Exp Hematol. 2023;118:40–52. doi:10.1016/j.exphem.2022.12.003
   PubMed Web of Science ®Google Scholar
• Mahdloo T, Sahami P, Ramezani R, et al. Up-regulation of miR-155 potentiates CD34+ CML stem/progenitor cells to escape from the growth-inhibitory effects of TGF-ss1 and BMP signaling. EXCLI J. 2021;20:748–763.
   PubMed Web of Science ®Google Scholar
• Liu W, He J, Yang Y, et al. Upregulating miR-146a by physcion reverses multidrug resistance in human chronic myelogenous leukemia K562/ADM cells. Am J Cancer Res. 2016;6(11):2547–2560.
   PubMed Web of Science ®Google Scholar
• Guo G, Kang Q, Zhu X, et al. A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA. Oncogene. 2015;34(14):1768–1779. doi:10.1038/onc.2014.131
   PubMed Web of Science ®Google Scholar
• Golestaneh AF, Lecker LSM, Schlegel J, et al. Large scale in vivo micro-RNA loss of function screen identified miR-29a, miR-100 and miR-155 as modulators of radioresistance and tumor-stroma communication. Int J Cancer. 2019;144(11):2774–2781. doi:10.1002/ijc.32019
   PubMed Web of Science ®Google Scholar
• Ocheni S, Iwanski GB, Schafhausen P, et al. Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leuk Lymphoma. 2009;50(4):551–558. doi:10.1080/10428190902755513
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv41–iv51. doi:10.1093/annonc/mdx219
   PubMed Web of Science ®Google Scholar
• Yuri P, Hendri AZ, Danarto R. Association between tumor-associated macrophages and microvessel density on prostate cancer progression. Prostate Int. 2015;3(3):93–98. doi:10.1016/j.prnil.2015.06.002
   PubMedGoogle Scholar
• Yap E, Norziha ZA, Simbun A, et al. MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations. Leuk Res. 2017;59:32–40. doi:10.1016/j.leukres.2017.05.015
   PubMed Web of Science ®Google Scholar
• Shulman DS, Lee MA, Lehmann LE, et al. Outcomes following bone marrow transplantation in children with accelerated phase or blast crisis chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. J Pediatr Hematol Oncol. 2016;38(8):610–614. doi:10.1097/MPH.0000000000000636
   PubMed Web of Science ®Google Scholar
• Senapati J, Jabbour E, Kantarjian H, et al. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia. 2023;37(1):5–17. doi:10.1038/s41375-022-01736-5
   PubMed Web of Science ®Google Scholar
• Martinovic Z, Kovac D, Martinovic C. Recurrences in stage II rectal carcinoma after curative resection alone: from the viewpoint of angiogenesis. World J Surg Oncol. 2016;14:122. doi:10.1186/s12957-016-0877-6
   PubMed Web of Science ®Google Scholar
• Cantu De Leon D, Lopez-Graniel C, Frias Mendivil M, et al. Significance of microvascular density (MVD) in cervical cancer recurrence. Int J Gynecol Cancer. 2003;13(6):856–862. doi:10.1136/ijgc-00009577-200311000-00018
   PubMed Web of Science ®Google Scholar
• Shi Z, Li Y, Qian X, et al. MiR-340 inhibits triple-negative breast cancer progression by reversing EZH2 mediated miRNAs dysregulated expressions. J Cancer. 2017;8(15):3037–3048. doi:10.7150/jca.19315
   PubMed Web of Science ®Google Scholar
• Flatmark K, Borgen E, Nesland JM, et al. Disseminated tumour cells as a prognostic biomarker in colorectal cancer. Br J Cancer. 2011;104(9):1434–1439. doi:10.1038/bjc.2011.97
   PubMed Web of Science ®Google Scholar
• Xiao C, Hong H, Yu H, et al. MiR-340 affects gastric cancer cell proliferation, cycle, and apoptosis through regulating SOCS3/JAK-STAT signaling pathway. Immunopharmacol Immunotoxicol. 2018;40(4):278–283. doi:10.1080/08923973.2018.1455208
   PubMed Web of Science ®Google Scholar
• Huang Z, Xu Y, Wan M, et al. miR-340: a multifunctional role in human malignant diseases. Int J Biol Sci. 2021;17(1):236–246. doi:10.7150/ijbs.51123
   PubMed Web of Science ®Google Scholar
• Qin Y, Zhou X, Huang C, et al. Lower miR-340 expression predicts poor prognosis of non-small cell lung cancer and promotes cell proliferation by targeting CDK4. Gene. 2018;675:278–284. doi:10.1016/j.gene.2018.06.062
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhou Q, Luo F, et al. Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAATbeta axis. Hum Cell. 2021;34(5):1558–1568. doi:10.1007/s13577-021-00564-6
   PubMed Web of Science ®Google Scholar
• Cui F, Hao ZX, Li J, et al. SOX2 mediates cisplatin resistance in small-cell lung cancer with downregulated expression of hsa-miR-340-5p. Mol Genet Genomic Med. 2020;8(5):e1195. doi:10.1002/mgg3.1195
   PubMed Web of Science ®Google Scholar
• Soltani I, Bahia W, Farrah A, et al. Potential functions of hsa-miR-155-5p and core genes in chronic myeloid leukemia and emerging role in human cancer: a joint bioinformatics analysis. Genomics. 2021;113(4):1647–1658. doi:10.1016/j.ygeno.2021.04.014
   PubMed Web of Science ®Google Scholar
• Rokah OH, Granot G, Ovcharenko A, et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One. 2012;7(4):e35501. doi:10.1371/journal.pone.0035501
   PubMed Web of Science ®Google Scholar
• Fallah P, Amirizadeh N, Poopak B, et al. Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Int J Lab Hematol. 2015;37(4):560–568. doi:10.1111/ijlh.12351
   PubMed Web of Science ®Google Scholar